News: DUSA Pharmaceuticals, Inc (DUSA.O)

DUSA.O on Consolidated Issue listed on NASDAQ Global Market

1.34USD
3:54pm EST
Price Change (% chg)

$0.04 (+3.08%)
Prev Close
$1.30
Open
$1.33
Day's High
$1.37
Day's Low
$1.26
Volume
51,888
Avg. Vol
67,896
52-wk High
$1.80
52-wk Low
$0.88

view news for:
Select another date:

Wed, Oct 22 2008

UPDATE 1-Dusa to stop developing acne treatment; shares fall

Oct 22 (Reuters) - Dusa Pharmaceuticals will stop developing its Levulan Photodynamic Therapy to treat moderate to severe acne, after the proposed treatment combination failed to show statistically significant results in a mid-stage trial.

Continue Reading

Study backs laser treatment for sun-damaged skin

WASHINGTON (Reuters) - A procedure using a topical solution made by DUSA Pharmaceuticals Inc and laser treatment stimulates collagen production and helps rejuvenate sun-damaged skin, U.S. researchers said on Monday.

Study backs laser treatment for sun-damaged skin

WASHINGTON, Oct 20 (Reuters) - A procedure using a topical solution made by DUSA Pharmaceuticals Inc and laser treatment stimulates collagen production and helps rejuvenate sun-damaged skin, U.S. researchers said on Monday.

Dusa Pharma files $75 mln mixed shelf offering

May 16 (Reuters) - Dusa Pharmaceuticals Inc said on Friday it may periodically sell up to $75 million shares in debt securities, common and preferred stock, warrants and depositary shares.

US RESEARCH NEWS-BMO cuts CCL Industries price target

Following are the research actions reported by Reuters on Monday as of 0835 ET. For research actions reported earlier in the day, please double click on [nBNG176810] For a snapshot of research actions, please double click on [SNAP/RCH] --------------------------------------------------------------- ------------ STOCK RESEARCH BY ACTION CCL Industries BMO Cuts price target to C$45 from C$48; has ou

Dusa Pharmaceuticals Inc Q3 results

DUSA PHARMACEUTICALS INC : * Third quarter GAAP per share loss $0.10 * Third quarter revenue $5.78 million * Third quarter non-GAAP per share loss $0.07 * Reuters Estimates third quarter earnings per share view $-0.16, revenue view $5.91 million

UPDATE 3-Dusa, River's Edge settle acne drug patent suit

BANGALORE, Oct 29 (Reuters) - Dusa Pharmaceuticals Inc said privately held River's Edge Pharmaceuticals LLC agreed to make a lump sum payment for damages, and permanently stop manufacture and sale of a generic version of its acne drug Nicomide, sending Dusa shares up more than 20 percent.

Dusa, River's Edge settle on Nicomide patent case

Oct 29 (Reuters) - Dusa Pharmaceuticals Inc said River's Edge Pharmaceuticals LLC accepted the validity of Dusa's patent on its acne drug, Nicomide, and agreed to make a lump-sum payment for damages.

TABLE-Dusa Pharmaceuticals Q2 results

DUSA PHARMACEUTICALS INC.

DUSA Pharmaceuticals names president to added CEO post

June 14 (Reuters) - Dermatology pharmaceutical company DUSA Pharmaceuticals Inc. said President Robert Doman was named to the additional position of chief executive officer.

Select another date:

Market Views

Press Releases

view news for: